Avitar's Expanded Product Line Simplifies Implementation of a Successful Drug-Free Workplace

Additional Service Offerings Help Companies Implement Drug-Free Workplace Programs 


CANTON, Mass., April 17  /PRNewswire-FirstCall/ -- Avitar, Inc. (OTC:AVTI.OB) (BULLETIN BOARD: AVTI.OB)  today announced the availability of additional services to aid corporations in implementing and managing successful drug-free workplace programs.   In cooperation with its specialized business partners, Avitar offers industry an integrated drug-free workplace solution.

"Drug abuse remains a serious threat to workplace safety as a significant financial cost across America's corporate markets," said Pete Phildius, Chairman & CEO of Avitar.  "Traditional pre-employment urine laboratory testing, and other compliance measures such as installing access control systems or security cameras have not significantly reduced workplace drug abuse.   We are pleased to be able to provide companies and employees with an expanded drug-free workplace solution that helps create safer work environments as well as delivers significant bottom-line cost savings."

Working with its business partners, Avitar's turn-key drug-free workplace solution incorporates the following elements:

  -- Drug-free workplace policy review/development
  -- Oral fluid-based on-site and laboratory drug testing, with a focus upon
     RANDOM drug testing.   (Additional modes of testing also include: pre-
     employment, post-accidents, reasonable cause, and return-to-duty)
  -- Employee drug education and awareness programs
  -- Supervisor training in how to recognize signs of drug abuse
  -- Quantitative confirmatory drug testing (GC/LC/MS)
  -- Medical review officer (MRO) services
  -- Web-based information management
  -- Employee assistance programs (EAPs)
  -- Drug-free workplace audits and assessments



"The programs we offer help corporations dramatically reduce substance abuse in the workplace by making drug and alcohol abuse a socially unacceptable behavior," continued Phildius.  "Our products and services empower companies and their employees to deter substance abuse and be able to protect the workplace from unsafe behaviors."

About Avitar, Inc.

Avitar, Inc. develops, manufactures and markets innovative and proprietary products. Their field includes the oral fluid diagnostic market, the disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry.  Avitar manufactures ORALscreen(R), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, as well as HYDRASORB(R), an absorbent topical dressing for moderate to heavy exudating wounds.  Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy.  For more information, see Avitar's website at http://www.avitarinc.com/.

Forward-Looking Statements

This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.

  Contact:
  Peter Cholakis
  Vice President - Marketing
  Avitar, Inc.
  781-821-2440, x117
  
  http://www.avitarinc.com/

DATASOURCE: Avitar, Inc.



Contact:  Peter Cholakis, Vice President of Marketing of Avitar, Inc.,

[phone], ext. 117, 



Web site:  http://www.avitarinc.com/ 

Copyright